SEHK:6990
SEHK:6990Biotechs

Should Kelun-Biotech’s MediLink Settlement and 2026 Framework Deals Reshape SEHK:6990’s Operating Playbook?

Sichuan Kelun-Biotech Biopharmaceutical has called an extraordinary general meeting for 31 December 2025 to approve several 2026 framework agreements covering promotional services, auxiliary R&D support, and procurement and sale of equipment and materials, while also settling trade secret and civil litigation disputes with MediLink Therapeutics through a profit- and income-sharing arrangement. By simultaneously formalising future operating relationships and removing legal uncertainty via the...
SEHK:6078
SEHK:6078Healthcare

Hygeia Healthcare (SEHK:6078) Is Up 10.8% After Launching a 10% Share Buyback Plan – Has The Bull Case Changed?

Hygeia Healthcare Holdings Co., Limited (SEHK:6078) has begun repurchasing its own shares under a shareholder-approved mandate allowing buybacks of up to 61,849,900 shares, alongside a separate program of up to CNY 300,000,000 announced on December 15, 2025. The twin authorizations, representing as much as 10% of issued share capital, highlight management’s focus on boosting net assets and earnings per share through capital management. We’ll now examine how this sizeable buyback...
SEHK:2142
SEHK:2142Biotechs

HBM Holdings (SEHK:2142): Valuation Check After Bristol Myers Squibb Collaboration Validates Growth Prospects

HBM Holdings (SEHK:2142) just landed a multi year global collaboration and license deal with Bristol Myers Squibb, tying its antibody discovery platform to potentially more than $1.1 billion in future payments. See our latest analysis for HBM Holdings. The market has already started to reprice that validation, with a 1 day share price return of 6.6 percent pushing HBM Holdings to HK$13.34. Its roughly 574 percent year to date share price return and nearly 896 percent 1 year total shareholder...
SEHK:6060
SEHK:6060Insurance

Debt Redemption And Premium Growth Could Be A Game Changer For ZhongAn Online (SEHK:6060)

ZhongAn Online P & C Insurance Co., Ltd. has announced it will redeem all of its remaining US$360,100,000 Notes on January 13, 2026, paying principal plus accrued interest and subsequently delisting the Notes from the Hong Kong Stock Exchange. Alongside this debt redemption plan, the company has reported 5.63% premium income growth driven by health and automobile insurance, and confirmed chairman Yin Hai’s continued leadership, underscoring both operating momentum and governance...
SEHK:1109
SEHK:1109Real Estate

Will Renewed Intragroup Financing and Service Pacts Change China Resources Land's (SEHK:1109) Narrative?

On 9 December 2025, China Resources Land renewed and expanded its continuing connected transactions framework agreements with CR Bank, CR Trust, CR Leasing, CR Digital, CRH and CRI, and signed new construction management and value-added services frameworks, each running for three years to the end of 2028. The refreshed suite of agreements helps lock in access to group financing, leasing, digital and operational support that underpin China Resources Land’s business model and project...
SEHK:2282
SEHK:2282Hospitality

MGM China (SEHK:2282): Assessing Valuation After Kenneth Xiaofeng Feng Steps In as CEO

MGM China Holdings (SEHK:2282) has just promoted long time insider Kenneth Xiaofeng Feng to chief executive officer, a leadership shift that could subtly reshape how investors think about the company’s Macau centric growth story. See our latest analysis for MGM China Holdings. The timing of Feng’s promotion coincides with strong momentum at MGM China. The share price stands at HK$16.61, with a year-to-date share price return of 64.78 percent contributing to a 1-year total shareholder return...
SEHK:6682
SEHK:6682Software

How Board and Governance Changes Will Impact Beijing Fourth Paradigm Technology (SEHK:6682) Investors

On 19 December 2025, Beijing Fourth Paradigm Technology Co., Ltd. approved amendments to its Articles of Association and confirmed board changes, including the resignation of independent non-executive director Mr. Liu Zhuzhan and the appointment of Mr. Pan Jialin at its shareholder meetings. With shareholders strongly backing these governance updates and the refreshed board composition, the company has highlighted a clearer corporate governance structure across its Hong Kong and mainland...
SEHK:916
SEHK:916Renewable Energy

Assessing China Longyuan Power Group (SEHK:916)’s Valuation After Strong November 2025 Renewable Output Growth

China Longyuan Power Group (SEHK:916) just posted upbeat November 2025 production numbers, with total generation up 14% year on year as wind output increased and PV generation rose on continued renewable expansion. See our latest analysis for China Longyuan Power Group. Even with the upbeat November numbers, the share price has been under pressure recently, with a 90 day share price return of minus 12.30%. However, the 5 year total shareholder return of 7.15% suggests the longer term...
SEHK:669
SEHK:669Machinery

A Look at Techtronic Industries (SEHK:669) Valuation as It Winds Down HART to Refocus on Core Brands

Techtronic Industries (SEHK:669) just announced it will wind down its HART business by the end of 2025, keeping the brand but doubling down on Milwaukee and Ryobi in a clear push toward higher margin growth. See our latest analysis for Techtronic Industries. The decision to exit HART comes after a choppy stretch, with a 30 day share price return of 9.29 percent but a year to date share price return of negative 8.66 percent, while the three year total shareholder return remains modestly...
SEHK:512
SEHK:512Pharmaceuticals

How Positive Phase II Depression Trial Data For GPN01360 At Grand Pharmaceutical Group (SEHK:512) Has Changed Its Investment Story

Earlier this month, Grand Pharmaceutical Group announced that its innovative traditional Chinese medicine GPN01360 met the primary and multiple secondary endpoints in a randomized, double-blind, placebo-controlled Phase II depression trial in China, showing significant symptom improvement and favorable safety over eight weeks. The result not only advances GPN01360 as a potential new option for depression with anxiety and insomnia, but also underlines Grand Pharmaceutical’s effort to extend...
SEHK:3898
SEHK:3898Machinery

Zhuzhou CRRC Times Electric (SEHK:3898): Valuation Check After New Long-Term Supply Deals and Governance Updates

Zhuzhou CRRC Times Electric (SEHK:3898) has just locked in fresh mutual supply agreements with CRRC Group and Qingdao Company for 2026 to 2028, reinforcing long term operating visibility and governance-driven investor confidence. See our latest analysis for Zhuzhou CRRC Times Electric. Those long term supply deals land at a time when the share price, now at HK$38.58, has already logged a strong year to date share price return and a solid 1 year total shareholder return. This suggests momentum...
SEHK:1378
SEHK:1378Metals and Mining

Will Index Inclusion in HSCEI Change China Hongqiao Group's (SEHK:1378) Investment Narrative?

In December 2025, China Hongqiao Group Limited was added to the Hang Seng China Enterprises Index, marking its inclusion among major Hong Kong–listed mainland enterprises. This index inclusion can broaden the company’s investor base as passive funds and benchmarked mandates adjust portfolios to reflect the new constituent. We will now explore how Hongqiao’s entry into the Hang Seng China Enterprises Index shapes its investment narrative and perceived market relevance. The end of cancer?...
SEHK:2005
SEHK:2005Pharmaceuticals

SSY Group (SEHK:2005): Valuation Check After New China Drug Approvals Expand Commercial Portfolio

SSY Group (SEHK:2005) just cleared an important regulatory hurdle in China, securing NMPA approvals for its Levofloxacin Eye Drops and Compound Sodium Picosulfate Granules, both passing consistency evaluations that support broader commercialization. See our latest analysis for SSY Group. Despite the positive news, SSY Group’s HK$2.96 share price still reflects a muted mood, with a negative year to date share price return and a three year total shareholder return that suggests sentiment has...